<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113058</url>
  </required_header>
  <id_info>
    <org_study_id>GDT-HBV-01-QK</org_study_id>
    <nct_id>NCT03113058</nct_id>
  </id_info>
  <brief_title>&quot;Treatment of Active HBV With γδT Cells&quot; Clinical Trial Protocol</brief_title>
  <official_title>&quot;Treatment of HBeAg-positive Chronic Hepatitis B With γδT Cells&quot; Clinical Trial Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jinan University Guangzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guagnzhou Qiaokang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jinan University Guangzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and anti-HBV efficacy of γδT cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this clinical trial, we will thoroughly evaluate the safety of in vitro expanded γδT
      cells, including allogeneic originated γδT cells, in clinical treatment of active HBV. At the
      same time, we will carefully and thoroughly examine and evaluate the clinical efficacy of γδT
      cells against active HBV, including lowering speed of DNA copy number, and the transferring
      rate of HBeAg from positive to negative.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 5, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DNA copy number</measure>
    <time_frame>6 months</time_frame>
    <description>Whether or not the DNA copy number in patients can be lowered more faster than those do not received T cell treatment in 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Negative conversion rate of HbeAg</measure>
    <time_frame>6 months</time_frame>
    <description>We will evaluate whether or not γδT Cells treatment could speed up Negative conversion rate of HbeAg.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Adoptive Treatment for Hepatitis B With γδT Cells</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Adoptive transfer of γδT cells</intervention_name>
    <description>Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Aged 18-45 years old, male or female; 2. Informed consent; 3. Patient who were
             tested HBsAg and HBeAg positive; 4. HBV DNA loads＞1 million copy/ml;5. Liver function
             test alanine aminotransferase (ALT) 160 IU/L≤400 IU/L; 6. No jaundice, total bilirubin
             is normal;7. For patients with new onset, oral antiviral drugs limited for Sebivo.

        Exclusion Criteria:

          -  1. Pregnant women;2. Patients Complicated with other viruses, bacteria infections and
             other infectious diseases;3. With other diseases such as diabetes, cancer,
             hypertension, coronary heart disease, endocrine system disease, mental illness,
             neurological disease, vascular circulation system diseases and so on, and after
             clinical doctors diagnose, evaluate the immune cells are not suitable for treatment of
             patients;4. There is no immediate relatives, immediate family members suffering from
             infectious diseases including e antigen positive, or immediate family is not suitable
             for patients as white blood cells supplier;5. Other indications that is not suitable
             for the treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhinan Yin, Ph.D.</last_name>
    <phone>(+86)18818801179</phone>
    <email>zhinan.yin@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yangzhe Wu, Ph.D.</last_name>
    <phone>(+86)18826469480</phone>
    <email>190374157@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guagnzhou Qiaokang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ren X Lai, bachelor</last_name>
      <phone>+86-15920368701</phone>
      <email>huitou_2007@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jinan University Guangzhou</investigator_affiliation>
    <investigator_full_name>Zhinan Yin, Ph.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HBV infection,γδT cells,Adoptive treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

